Related Experiment Video
Updated: Aug 11, 2026
Retinal Pathophysiological Evaluation in a Rat Model
Published on: May 6, 2022
Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model
H P Hammes1, D Strödter, A Weiss
1Third Medical Department, Justus-Liebig-University, Giessen, Germany.
Abstract:
Primary prevention with aminoguanidine-an inhibitor of advanced glycation end product (AGE) formation--has been successfully employed to prevent diabetic retinopathy in the rat. However, it is unknown whether inhibition of AGE formation is still effective in a secondary intervention strategy. The present study addresses this question by comparing secondary intervention with aminoguanidine with syngeneic islet transplantation in the rat model. After 6 months of diabetes, one group was treated with aminoguanidine (50 mg/100 ml drinking water; D-AG) while another group received syngeneic transplantation of collagenase-ficoll isolated islets by intraportal injection (Tx). After an additional 4 months, both groups were compared to a normal (NC 10) and diabetic (DC 10) control group. Retinal autofluorescence was increased 2.5-fold after 6 months and increased 3.7-fold after 10 months of diabetes (p < 0.001). Aminoguanidine and islet Tx retarded the further accumulation of autofluorescence equally (p < 0.001 vs DC 10), although the values were higher than those observed in DC at 6 months (p < 0.001). Diabetes was associated with a 2.7-fold increase in acellular capillaries after 6 months and a 4.1-fold increase after 10 months. Treatment with aminoguanidine or islet Tx reduced but did not completely attenuate the progression of vascular occlusion (p < 0.001 vs DC 10; D-AG vs DC 6, p < 0.05; Tx vs DC 6, p < 0.01). Both treatments reduced endothelial proliferation (22.4% after 10 months; p < 0.001) and completely arrested pericyte dropout (40% after 10 months; p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Secondary intervention with aminoguanidine or islet transplantation slowed diabetic retinopathy progression in rats. Both treatments reduced retinal autofluorescence and vascular changes, offering potential therapeutic strategies.
Area of Science:
- Ophthalmology
- Diabetology
- Pharmacology
Background:
- Diabetic retinopathy is a leading cause of blindness.
- Primary prevention of diabetic retinopathy using aminoguanidine (an inhibitor of advanced glycation end product formation) has shown success.
- The efficacy of inhibiting advanced glycation end product formation as a secondary intervention for diabetic retinopathy remains unclear.
Purpose of the Study:
- To investigate the effectiveness of aminoguanidine as a secondary intervention for diabetic retinopathy.
- To compare aminoguanidine treatment with syngeneic islet transplantation in a rat model of diabetes.
Main Methods:
- Rats with 6 months of diabetes were treated with aminoguanidine or syngeneic islet transplantation for an additional 4 months.
- Retinal autofluorescence, acellular capillaries, endothelial proliferation, and pericyte dropout were assessed.
- Treatment groups were compared to normal and diabetic control groups.
Main Results:
- Both aminoguanidine and islet transplantation significantly retarded the accumulation of retinal autofluorescence compared to diabetic controls.
- Vascular occlusion progression was reduced but not completely attenuated by either treatment.
- Endothelial proliferation was reduced, and pericyte dropout was completely arrested by both interventions.
Conclusions:
- Aminoguanidine and islet transplantation demonstrate efficacy as secondary interventions in a rat model of diabetic retinopathy.
- Inhibition of advanced glycation end product formation and islet transplantation can mitigate key pathological features of diabetic retinopathy.
- These findings suggest potential therapeutic avenues for managing established diabetic retinopathy.
More Related Videos
Related Concept Videos
01:27Diabetic Retinopathy
01:28Diabetic Nephropathy